ライフサイエンスコーパス: IVUS

1 IVUS analysis included qualitative and quantitative meas

2 IVUS assessment of IFM in chronic Type B aortic dissecti

3 IVUS guidance compared with angiography guidance was ass

4 IVUS guidance has benefits in improving the long-term pr

5 IVUS has been used in clinical trials to evaluate the ef

6 IVUS is a feasible imaging modality that may be useful i

7 IVUS minimum lumen diameter (MLD), minimum lumen area (M

8 IVUS was associated with an independent and significant

9 IVUS was associated with larger stent diameters (median,

10 IVUS was performed at baseline and study completion.

11 IVUS was utilized in 3349 patients (39%), and larger-dia

12 Baseline 3D IVUS was performed at 0.22 (0.17-1.16) years after trans

13 10 H+LTx recipients in whom two coronary 3D IVUS studies were performed 1 year apart.

14 ars after transplantation, with follow-up 3D IVUS exams performed after baseline exam (0.96 [0.83-1.0

15 Again, IVUS did not disclose this heterogeneity.

16 For amlodipine, IVUS showed evidence of slowing of atherosclerosis progr

17 We conclude that (1) an IVUS MLD and MLA of 2.8 mm and 5.9 mm2, respectively, st

18 Ultrasound signals were obtained using an IVUS system with a 40-MHz catheter and digitized at 1 GH

19 and stent thrombosis might be lower with an IVUS-guided approach.

20 of OCT (AUC: 0.70; 95% CI: 0.55 to 0.83) and IVUS (AUC. 0.63; 95% CI: 0.47 to 0.77; p = 0.19).

21 Standard clinical, angiographic, and IVUS measurements were collected and/or measured.

22 Both CFDI and IVUS depict the blood flow and endoluminal abnormalities

23 The observation that CFDI and IVUS depicted endoluminal abnormalities suggestive of RA

24 CT, or invasive examinations such as DSA and IVUS.

25 ure guidewire was used to calculate FFR, and IVUS parameters were calculated after automatic pullback

26 the feasibility of integrating EIS, ISS, and IVUS for a catheter-based approach to assess mechanicall

27 struts were no longer discernable by OCT and IVUS.

28 VUS) data were acquired from 14 patients and IVUS-based 3D fluid-structure interaction (FSI) coronary

29 The average IVUS area stenosis was markedly greater in RAS with an H

30 Integrated backscatter IVUS has a better potential for characterizing fibrous l

31 Compared with baseline, IVUS showed progression in the placebo group (P<.001), a

32 erformed to examine the relationship between IVUS guidance and 1-year outcomes.

33 r coronary plaque progression as assessed by IVUS, despite an increased prevalence of sensitized pati

34 ssion rate of atherosclerosis as detected by IVUS predicts cardiovascular outcomes is unknown.

35 Changes in atheroma volume, as determined by IVUS after adjustment for possible confounders by using

36 coronary arteries were previously imaged by IVUS and 130 arteries were not imaged by IVUS.

37 by IVUS and 130 arteries were not imaged by IVUS.

38 n of coronary atherosclerosis as measured by IVUS.

39 Anatomic measurements by IVUS show a moderate correlation with the FFR values.

40 NS), in-stent percent volume obstruction by IVUS (29% vs. 24%; p = NS), and clinically driven TLR (1

41 Rapidly progressive vasculopathy by IVUS, defined as an increase of >/=0.5 mm in intimal thi

42 patients, MDCT measurements were verified by IVUS.

43 However, comparisons among OCT, C-IVUS, and IB-IVUS have not been done.

44 The sensitivity of C-IVUS was 100%, 93%, and 67%, respectively.

45 The specificity of C-IVUS was 99%, 61%, and 95%, respectively (Cohen's kappa

46 izing fibrous lesions and lipid pools than C-IVUS.

47 and conventional intravascular ultrasound (C-IVUS) for tissue characterization of coronary plaques an

48 tes (42 coronary arteries) from 17 cadavers; IVUS and OCT images were acquired on the same slice as h

49 g coronary angiography is often challenging; IVUS provides useful information for assessment of coron

50 l was constructed based on a 40 MHz clinical IVUS catheter.

51 e, discuss some of the concerns, and compare IVUS results with those of quantitative arteriography.

52 was performed in all cases, with concomitant IVUS imaging in 47 cases.

53 We conducted IVUS studies on 214 patients with angiographically indet

54 After adjusting for potential confounders, IVUS was associated with significantly lower occurrence

55 ine and one year) were re-analyzed at a core IVUS laboratory.

56 Our preliminary serial 3D coronary IVUS data show that H+LTx attenuates cardiac allograft v

57 Patients underwent a baseline coronary IVUS, which was repeated after 2 years of amlodipine, en

58 lumen volumes were compared between coronary IVUS studies at baseline and follow-up.

59 respective of performance of second coronary IVUS.

60 ee-dimensional intravascular ultrasound (3-D IVUS) examination of the left anterior descending corona

61 -DES, the largest study of IVUS use to date, IVUS guidance was associated with a reduction in stent t

62 Three-dimensional IVUS was performed after intervention and at 9-month fol

63 Two-dimensional IVUS measurements and vessel, lumen and plaque volume we

64 provides higher resolution imaging than does IVUS, although findings from some studies suggest that i

65 nt for differences in baseline risk factors, IVUS-guidance was associated with significantly lower in

66 t to target lumen revascularization favoring IVUS-guided coronary stent implantation, it is likely th

67 ability to safely acquire co-registered FLIm-IVUS data in vivo using Dextran40 solution flushing was

68 The unique FLIm-IVUS system evaluated here has the potential to provide

69 composition was high for IVMRI but poor for IVUS.

70 The results were similar for IVUS-defined ISR (odds ratio: 0.42; 95% confidence inter

71 Sensitivity/specificity for IVUS was 67%/65% for an optimal cutoff value of 2.36 mm(

72 Macrovascular disease was evaluated from IVUS studies and assigned into one of five grades based

73 scuss the critical information obtained from IVUS and FFR in guiding treatment of patients with inter

74 at has recently been combined with grayscale IVUS in a single catheter as the first combined imaging

75 three, stratified by site) to OCT guidance, IVUS guidance, or angiography-guided stent implantation.

76 ient) were measured by a pressure guidewire; IVUS and angiographic parameters (minimum lumen area and

77 ss the correlation between virtual histology IVUS and FFR for intermediate coronary lesions.

78 However, IVUS analysis for macrovascular disease revealed mostly

79 enetration depth simultaneously, this hybrid IVUS-OCT technology opens new and safe opportunities to

80 wever, comparisons among OCT, C-IVUS, and IB-IVUS have not been done.

81 The sensitivity of IB-IVUS was 100%, 94%, and 84%, respectively.

82 The specificity of IB-IVUS was 99%, 84%, and 97%, respectively (Cohen's kappa

83 ted backscatter intravascular ultrasound (IB-IVUS), and conventional intravascular ultrasound (C-IVUS

84 This study aimed to determine if IVUS-guided stent implantation is associated with improv

85 Balloon angioplasty eliminates or improves IVUS findings and produces substantial, sustained BP red

86 hundred and three patients were included in IVUS arms.

87 mum interstrut angle as the only independent IVUS predictor of IH cross-sectional area (P<0.01 and P<

88 Initially, IVUS was shown to be able to characterize plaque broadly

89 We reviewed 791 pre-intervention IVUS SVG studies and identified 95 ruptured plaques in 7

90 <65 years of age underwent pre-intervention IVUS within 2 days from onset of an MI.

91 ; grayscale intravascular ultrasound (IVUS); IVUS radiofrequency tissue characterization; optical coh

92 eluting stents for diffuse coronary lesions, IVUS-guided percutaneous coronary intervention is superi

93 and only the main vessel (MV) in 15 lesions; IVUS analysis included five distinct locations: MV proxi

94 igh lead extraction difficulty score had low IVUS grade, and the degree of transvenous lead extractio

95 difficulty was similar to patients with low IVUS grades and lead extraction difficulty scores.

96 seline and follow-up at 16.2 +/- 7.4 months) IVUS findings in 50 nonintervened SVG segments in 44 pat

97 A motorized IVUS pullback was used to assess coronary atheroma burde

98 onic stable angina patients with multivessel IVUS imaging.

99 gher inflation pressures were used in 74% of IVUS-guided cases.

100 The ability of IVUS to detect vulnerable plaques before rupture is curr

101 coherence tomography, the light analogue of IVUS; and near-infrared spectroscopy that detects lipid

102 troduces a challenge to standard analyses of IVUS outcomes relying on constant stent diameters over t

103 Recent advances in new applications of IVUS, such as integrated backscatter, wavelet analysis,

104 The benefits of IVUS were especially evident in patients with acute coro

105 , the safety, efficacy, and effectiveness of IVUS should be taken into account when considering the g

106 We studied the impact of IVUS guidance on outcome in patients undergoing unprotec

107 In addition, the importance of IVUS and FFR in the management of patients with serial s

108 Although multiple measures of IVUS disease burden were worse in subjects with diabetes

109 In ADAPT-DES, the largest study of IVUS use to date, IVUS guidance was associated with a re

110 ted in similar minimum stent area to that of IVUS-guided PCI.

111 The utility of IVUS MLA as an alternative to FFR to guide intervention

112 The utility of IVUS to assure adequate stent expansion may be more impo

113 However, the cutoff values of IVUS parameters at which to predict a fractional flow re

114 On IVUS, the minimum lumen area of B1 decreased from 5.23 +

115 On IVUS, various endoluminal defects (eccentric ridges; flu

116 nificant increases in plaque burden based on IVUS analyses.

117 lower ILA and extraction difficulty based on IVUS imaging.

118 e present in the clinical characteristics or IVUS parameters between the control and TAXUS groups.

119 In 340 propensity score-matched pairs, IVUS was also associated with significantly lower occurr

120 y multivessel (2.1 +/- 0.7 arteries/patient) IVUS examination 1.0 +/- 0.5 month and 12.0 +/- 1.0 mont

121 Of 2468 patients, IVUS guidance was used in 621 (25.2%).

122 Postintervention IVUS was performed in both branches in 25 lesions and on

123 with extensive calcification that precluded IVUS interpretation.

124 on of atherosclerosis for all 3 prespecified IVUS measures of disease burden.

125 The primary prespecified IVUS end point was the in-stent percent net volume obstr

126 The primary IVUS efficacy parameter, PAV, did not differ between par

127 Recent IVUS studies have suggested that patients presenting wit

128 We used a novel "regional" IVUS analysis to assess the mechanism of LSM.

129 Disease progression was measured by repeat IVUS examination after at least 72 weeks of treatment.

130 Repeated IVUS examinations following heart transplantation do not

131 ent atheroma volume (PAV), the most rigorous IVUS measure of disease progression and regression.

132 orted clinical outcomes and compared routine IVUS-guided stent implantation with an angiography-guide

133 However, routine IVUS guidance of coronary stent implantation is not supp

134 At a mean of 15 months, routine IVUS-guided percutaneous coronary intervention was assoc

135 The diagnostic accuracy of gray-scale IVUS to identify thin-capped fibroatheromata was poor fo

136 atory analysis, and compared with gray-scale IVUS.

137 The secondary IVUS efficacy parameter, TAV, did not differ between par

138 Serial IVUS is the most accurate method for early detection and

139 Serial IVUS studies reveal details of the pattern of vascular r

140 24 months, 349 patients had evaluable serial IVUS examinations.

141 There are no serial IVUS studies of disease progression or luminal compromis

142 tients in 6 clinical trials that used serial IVUS.

143 of the results in patients with simultaneous IVUS and OCT imaging revealed no significant differences

144 In this SIRIUS IVUS substudy, SES reduced both biologic variability and

145 The minimum lumen site had a smaller IVUS lumen area at follow-up (2.7+/-0.9 versus 6.2+/-1.9

146 ons was 41.6%; by near-infrared spectroscopy-IVUS, the median plaque burden was 73.7%, the median MLA

147 biochemical information that can supplement IVUS data for a comprehensive assessment of plaques path

148 iency (AUC: 0.77; 95% CI: 0.60 to 0.89) than IVUS (AUC: 0.63; 95% CI: 0.46 to 0.78) to identify funct

149 ial or future cardiovascular event risk that IVUS can serve as an efficient surrogate for clinical ev

150 The IVUS data demonstrated a numeric trend toward regression

151 The IVUS end point was change in percent atheroma volume.

152 The IVUS features of ruptured plaques included positive remo

153 The IVUS group was younger (median age, 70 versus 75 years)

154 The IVUS images were reviewed for the presence of ISA.

155 The IVUS mid-left anterior descending (LAD) luminal area was

156 The IVUS substudy showed a trend toward less progression of

157 The IVUS tapes (at baseline and one year) were re-analyzed a

158 The IVUS-defined rapid progression correlated highly with fu

159 The IVUS-detected ruptured plaques had angiographically comp

160 nderwent final OCT imaging (operators in the IVUS and angiography groups were masked to the OCT image

161 140 [34%] in the OCT group, 135 [33%] in the IVUS group, and 140 [34%] in the angiography group).

162 nts in the OCT group, one (1%) of 146 in the IVUS group, and one (1%) of 146 in the angiography group

163 djusted primary outcome trended lower in the IVUS-guided group versus the angiography-guided (6.9% vs

164 99; P=0.04) also appeared to be lower in the IVUS-guided group.

165 l assumptions, and the interpretation of the IVUS measurements that the answer cannot be taken for gr

166 imary powered effectiveness endpoint was the IVUS-derived minimum lumen area (MLA) at protocol-driven

167 ; findings must be put into context with the IVUS findings in bare metal stents.

168 Therefore, IVUS findings in low- and high-dose patients were combin

169 egative clinical events associated with this IVUS finding at 12-month clinical follow-up; however, ca

170 450 patients (158 [35%] to OCT, 146 [32%] to IVUS, and 146 [32%] to angiography), with 415 final OCT

171 dices measured by MDCT correlated closely to IVUS (r(2) = 0.77 and r(2) = 0.82, respectively).

172 We tested non-inferiority of OCT guidance to IVUS guidance (with a non-inferiority margin of 1.0 mm(2

173 guidance, and superiority of OCT guidance to IVUS guidance, in a hierarchical manner.

174 OCT guidance was non-inferior to IVUS guidance (one-sided 97.5% lower CI -0.70 mm(2); p=0

175 Although OCT seems slightly superior to IVUS for this purpose (particularly in vessels <3 mm), i

176 red by serial intravascular ultrasonography (IVUS) imaging.

177 ce (IMR); and intravascular ultrasonography (IVUS) of the left anterior descending coronary artery, w

178 sed using intravascular coronary ultrasound (IVUS) and quantitative coronary angiography (QCA).

179 th complete serial intravascular ultrasound (IVUS) (baseline and 8-month follow-up) were analyzed.

180 s were imaged with intravascular ultrasound (IVUS) 5 and 10 min after ELIP injection (5-mg dose).

181 Intravascular ultrasound (IVUS) and cardiac MRI (CMR) were studied in patients wit

182 Intravascular ultrasound (IVUS) and fractional flow reserve index (FFR) provide an

183 relation with both intravascular ultrasound (IVUS) and histopathology for discrimination between soft

184 erosis assessed by intravascular ultrasound (IVUS) and its rate of progression in subjects treated wi

185 with a combination intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) catheter aft

186 tegrating EIS with intravascular ultrasound (IVUS) and shear stress (ISS) provided a new strategy to

187 oncomitant OCT and intravascular ultrasound (IVUS) area measurements were performed in a subgroup of

188 hypothesized that intravascular ultrasound (IVUS) could accurately visualize and quantify ILA and de

189 dity of first-year intravascular ultrasound (IVUS) data as a surrogate marker for long-term outcome a

190 Serial intravascular ultrasound (IVUS) data from the Reversal of Atherosclerosis with Agg

191 In vivo intravascular ultrasound (IVUS) data were acquired from 14 patients and IVUS-based

192 phy and volumetric intravascular ultrasound (IVUS) evaluation of the left anterior descending artery

193 Patients underwent intravascular ultrasound (IVUS) evaluation of the target vessel during the cathete

194 impact of repeated intravascular ultrasound (IVUS) examinations on transplant coronary artery disease

195 ue volume (CPV) by intravascular ultrasound (IVUS) examinations.

196 We report intravascular ultrasound (IVUS) findings after crush-stenting of bifurcation lesio

197 , it is unknown if intravascular ultrasound (IVUS) guidance for percutaneous coronary intervention sh

198 Intravascular ultrasound (IVUS) guidance has been shown to reduce major adverse ca

199 ggest a benefit of intravascular ultrasound (IVUS) guidance in noncomplex lesions.

200 etter outcome with intravascular ultrasound (IVUS) guidance when performing unprotected left main cor

201 Intravascular ultrasound (IVUS) has become an indispensable part of all drug-eluti

202 Intravascular ultrasound (IVUS) has played an integral role in the evolution of in

203 Intravascular ultrasound (IVUS) has the ability to detect and localize plaque as w

204 rdial biopsies and intravascular ultrasound (IVUS) images of coronary arteries in 33 heart transplant

205 underwent coronary intravascular ultrasound (IVUS) imaging and were randomized to receive 300 mg of a

206 e tomography (OCT)-intravascular ultrasound (IVUS) imaging at 72 frames per second safely in vivo, i.

207 Intravascular ultrasound (IVUS) is being used to assess the significance of a left

208 Although intravascular ultrasound (IVUS) is widely used to detect early transplant coronary

209 er the guidance of intravascular ultrasound (IVUS) or conventional angiography at a large single cent

210 High-frequency intravascular ultrasound (IVUS) revealed atherosclerotic lesions in the regions wi

211 ry angiography and intravascular ultrasound (IVUS) studies were performed annually to evaluate severi

212 rial 3-dimensional intravascular ultrasound (IVUS) studies were performed within 8 weeks (baseline; B

213 who completed the intravascular ultrasound (IVUS) substudy of the CAMELOT (Comparison of Amlodipine

214 umen area (MLA) by intravascular ultrasound (IVUS) that correlates with fractional flow reserve (FFR)

215 We used serial intravascular ultrasound (IVUS) to assess disease progression in nonintervened sap

216 s study was to use intravascular ultrasound (IVUS) to compare octogenarians versus patients <65 years

217 ent study analyzed intravascular ultrasound (IVUS) to define the changes that take place in the arter

218 nd preintervention intravascular ultrasound (IVUS) to determine the incidence and magnitude of SVG ca

219 We used intravascular ultrasound (IVUS) to evaluate recurrence after sirolimus-eluting ste

220 serial volumetric intravascular ultrasound (IVUS) to evaluate the effect of preinterventional arteri

221 serial volumetric intravascular ultrasound (IVUS) to evaluate the effects of polymer-based, paclitax

222 Prior intravascular ultrasound (IVUS) trials have demonstrated slowing or halting of ath

223 ergoing TEVAR with intravascular ultrasound (IVUS) were analysed and IFM was calculated.

224 y angiography, and intravascular ultrasound (IVUS) were evaluated in subjects enrolled in a study com

225 catheter combining intravascular ultrasound (IVUS) with multispectral fluorescence lifetime imaging (

226 e gradients (TPG), intravascular ultrasound (IVUS), and angiographic parameters in predicting hyperte

227 onth angiographic, intravascular ultrasound (IVUS), and clinical follow-up were conducted.

228 onary angiography, intravascular ultrasound (IVUS), and optical coherence tomography (OCT) at differe

229 ex imaging (CFDI), intravascular ultrasound (IVUS), and renal arteriography in diagnosing renal arter

230 Intravascular ultrasound (IVUS)-attenuated plaque is characterized by absence of u

231 ressive changes in intravascular ultrasound (IVUS)-derived indexes of plaque size sufficiently predic

232 Intravascular ultrasound (IVUS)-derived lumen, outer stent/scaffold, and reference

233 lationship between intravascular ultrasound (IVUS)-derived measures of atherosclerosis and cardiovasc

234 the efficacy of an intravascular ultrasound (IVUS)-guided strategy for patients with angiographically

235 al (3D) volumetric intravascular ultrasound (IVUS).

236 nsional volumetric intravascular ultrasound (IVUS).

237 ared with those of intravascular ultrasound (IVUS).

238 ell described with intravascular ultrasound (IVUS).

239 sis progression by intravascular ultrasound (IVUS).

240 que progression by intravascular ultrasound (IVUS).

241 CAG) alone or with intravascular ultrasound (IVUS).

242 reserve; grayscale intravascular ultrasound (IVUS); IVUS radiofrequency tissue characterization; opti

243 serial qualitative intravascular ultrasound (IVUS; at stent implantation and eight-month follow-up) w

244 011, a total of 1,899 patients who underwent IVUS-guided (n = 713, 37.5%) or conventional angiography

245 Each pair of baseline and follow-up IVUS assessments was analyzed in a blinded fashion.

246 analyzed poststenting and 13-month follow-up IVUS in 186 patients (195 lesions) with acute myocardial

247 tically significantly decreased at follow-up IVUS in patients who received beta-blockers (P < 0.001)

248 At nine-month follow-up, IVUS lumen volumes were larger in the TAXUS group (123 +

249 red before transvenous lead extraction using IVUS.

250 tient-based analysis of 64-slice CCTA versus IVUS showed a mean weighted sensitivity and specificity

251 VH-IVUS plaque classification, and particularly VH-IVUS-def

252 Local observers classified 100 VH-IVUS-defined coronary plaques to determine single center

253 aps against coregistered histology in 72 (VH-IVUS) and 87 (CT) segments from 8 postmortem coronary ar

254 A VH-IVUS assessment may add important information in the eva

255 However, although VH-IVUS could identify thin-cap fibroatheromas (TCFA) with

256 We also assessed VH-IVUS and CT Plaque Maps against coregistered histology i

257 (2)], p = 0.027) areas; however, baseline VH-IVUS plaque composition did not differ between VH-TCFAs

258 However, direct comparisons between VH-IVUS and OCT are lacking and it remains unknown whether

259 Both VH-IVUS and OCT can reliably identify TCFA, although OCT ac

260 The presence of VHD-IP as assessed by VH-IVUS is associated with early recurrent rejection and wi

261 Single-center VH-IVUS inter-observer agreement was strong (kappa=0.86), b

262 Combined VH-IVUS/OCT imaging markedly improved TCFA identification.

263 ification was 63.6%, 78.1%, and 76.5% for VH-IVUS and 72.7%, 79.8%, and 79.0% for OCT.

264 Differences in VH-IVUS plaque definitions introduce further variability be

265 accuracy of local versus core-laboratory VH-IVUS plaque classification and effects of different plaq

266 These factors reduce the use of VH-IVUS plaque classification to guide intervention in a "l

267 On VH-IVUS, plaque (10.91+/-4.82 versus 8.42+/-4.57 mm(2); P=0

268 S plaque classification, and particularly VH-IVUS-defined thin-capped fibroatheromata identification,

269 to pathological intimal thickening (PIT), VH-IVUS-derived thin-capped fibroatheroma (VH-TCFA), thick-

270 ferent plaque definitions further reduced VH-IVUS-defined thin-capped fibroatheromata numbers by 44%.

271 Based on the VH-IVUS plaque characteristics, coronary allograft plaque w

272 que components with a similar accuracy to VH-IVUS ex vivo.

273 rtual-histology intravascular ultrasound (VH-IVUS) and optical coherence tomography (OCT) can assess

274 rtual histology intravascular ultrasound (VH-IVUS) can identify plaques at high risk of rupture, such

275 rtual histology intravascular ultrasound (VH-IVUS) imaging to assess the presence and predictors of v

276 rtual histology intravascular ultrasound (VH-IVUS) in 108 plaques from 57 patients.

277 rtual histology intravascular ultrasound (VH-IVUS) to investigate the natural history of coronary art

278 coronary allograft vasculopathy underwent VH-IVUS examination of the left anterior descending coronar

279 serial (baseline and 12-month follow-up) VH-IVUS studies and examined 216 nonculprit lesions (plaque

280 gy and compared with coregistered ex vivo VH-IVUS and OCT.

281 ability was determined by comparison with VH-IVUS core-laboratory analysis, and compared with gray-sc

282 Plaque Maps correlated significantly with VH-IVUS-determined plaque component volumes (necrotic core:

283 roma (80% versus 79%) was comparable with VH-IVUS.

284 rt of a formal substudy, complete volumetric IVUS data were available in 170 patients, including 88 T

285 (1%) of 146 in the angiography group (OCT vs IVUS p=0.37; OCT vs angiography p=0.37).

286 Whether IVUS guidance is associated with improved clinical outco

287 th OCT guidance, 5.89 mm(2) (4.67-7.80) with IVUS guidance, and 5.49 mm(2) (4.39-6.59) with angiograp

288 similar to or better than that achieved with IVUS guidance and better than that achieved with angiogr

289 trials that employed serial assessments with IVUS.

290 directed antibodies are also associated with IVUS documented vasculopathy (P<0.002).

291 ctive stenosis not intended for PCI but with IVUS plaque burden of >=65% were randomized to treatment

292 d plaque volume per segment as compared with IVUS (24+/-35 mm3 versus 43+/-60 mm3, P<0.001).

293 alculated for each patient and compared with IVUS findings.

294 FFR correlates with IVUS findings and is abnormal in a significant proportio

295 ector row MDCTA show a good correlation with IVUS.

296 port the use of atherosclerosis imaging with IVUS in the evaluation of novel antiatherosclerotic ther

297 when performing unprotected LMCA PCI without IVUS guidance.

298 0 and December 2012 with baseline and 1-year IVUS were included.

299 First-year IVUS results and subsequent five-year clinical follow-up

300 gle-center studies have suggested first-year IVUS results might be a surrogate marker for long-term o